Landmark cancer trial shows success against pancreatic cancer, often described as undruggable.
The experimental drug, daraxonrasib, disarms all three members of the RAS family of proteins, which are notoriously difficult to target
#MedSky 🧪
www.nature.com/articles/d41...
Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.
